Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

NCT07314294 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: EMB-01 1600 mg administered once weekly throughout the study
DRUG: EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter

Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.